Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s Form 10-K for the fiscal year ended June 30, 2018, filed August 29, 2018. This does not match the request metadata identifying “Lite Strategy, Inc.” and “2016 Q4”; the summary below reflects the filing text provided.
Business context
MEI Pharma is a clinical-stage oncology drug developer with four candidates: pracinostat, ME-401, voruciclib and ME-344. It had no commercialized products. Pracinostat was in a global Phase 3 AML registration trial, while ME-401 was being advanced for relapsed or refractory follicular lymphoma. Helsinn bears primary responsibility for funding pracinostat’s global development and commercialization; MEI funds development of its other programs.
Financial performance and liquidity
Amounts below are in millions of dollars unless stated otherwise. Fiscal-year figures compare years ended June 30; the quarterly comparison is for the June quarters.
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Total revenue | $1.6 | $23.2 |
| Operating expenses | $30.2 | $20.9 |
| Operating income (loss) | ($28.6) | $2.4 |
| Net income (loss) | ($40.1) | $2.7 |
| Net loss per share, diluted | ($0.97) | $0.07 |
| Cash used in operating activities | $21.3 | Cash provided: $3.5 |
| Cash, equivalents and short-term investments at year-end | $102.7 | $53.6 |
| Total liabilities at year-end | $54.2 | $4.9 |
FY 2018 revenue consisted of $1.6 million of research and development revenue under the Helsinn agreement; there was no license revenue. FY 2017 included $20.9 million of license revenue recognized from the Helsinn upfront payment. The filing reports no commercial product revenue, so conventional product gross margins are not meaningful. FY 2018 included $9.7 million of non-cash warrant fair-value expense and $2.4 million of financing costs. The filing cites a $30.4 million net loss excluding the warrant fair-value expense.
At June 30, 2018, current assets were $104.3 million and current liabilities were $7.9 million. Total liabilities included a $46.3 million warrant liability; the filing does not identify conventional debt borrowings. Management expected existing cash and investments to fund operations into calendar 2020, while anticipating operating losses and negative operating cash flow. No off-balance-sheet arrangements were reported.
Material changes versus prior periods
- Revenue fell from $23.2 million to $1.6 million, primarily because the $20.9 million Helsinn license revenue was recognized in FY 2017.
- Research and development expense increased from $7.2 million to $17.0 million, including the $2.9 million voruciclib license payment and increased ME-401 manufacturing costs.
- Net results swung from $2.7 million income to a $40.1 million loss; the 2018 result was affected by the warrant remeasurement and financing costs.
- Cash and investments rose by $49.2 million year over year, supported by the May 2018 private placement, which generated approximately $70.2 million net proceeds. The company issued 33.0 million shares and warrants for 16.5 million additional shares.
- For the June 2018 quarter, revenue was $548,000 versus $449,000 in the June 2017 quarter; net loss was $19.3 million versus $4.3 million.
Outlook, management commentary and key risks
- Management planned to initiate a randomized global Phase 2 ME-401 study by the end of calendar 2018, targeting approximately 150 patients with follicular lymphoma after at least two prior systemic therapies. The filing states FDA support for the proposed trial, but accelerated approval would depend on FDA review and evidence of improvement over available therapies.
- The pracinostat Phase 3 trial was designed to enroll approximately 500 patients with AML. A Phase 2 MDS study expanded to 60 patients after meeting its interim discontinuation-rate threshold; its results could inform a registration study.
- ME-401 Phase 1b data included a 90% objective response rate among 30 evaluable patients, with limited follow-up. These early-stage findings are not proof of later-stage efficacy or approval.
- ME-344 interim breast-cancer study data showed a reported Ki-67 reduction; the reported comparisons were not statistically conclusive (P=0.06 and P=0.19). The study was continuing.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on Helsinn and other third parties, competition, manufacturing and intellectual-property risks, and the need for additional capital. The company warned that future financing could dilute shareholders; substantial warrants and options were outstanding.
- There is no operating history from product sales, no assurance of profitability, and no dividend expected in the foreseeable future. The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the requested issuer and period: the supplied document is MEI Pharma’s FY 2018 10-K, not a Lite Strategy, Inc. 2016 Q4 filing.
- Review subsequent clinical and regulatory results for pracinostat, ME-401, voruciclib and ME-344 against the plans and preliminary data described here.
- Assess cash runway against actual spending, trial costs and the stated calendar-2020 funding expectation.
- Examine dilution and warrant terms, including the 16.5 million warrants and their liability accounting, as well as outstanding options.
- Check the status of Helsinn collaboration obligations, potential milestones and royalties, and the company’s future financing needs.